English
Home > Products > CAS NO 182230-43-9

China CAS NO 182230-43-9 Factory

We keep on with the principle of "quality initial, service very first, ongoing improvement and innovation to meet the customers" for the administration and "zero defect, zero complaints" as the quality objective. To fantastic our assistance, we give the goods while using the fantastic high quality at the reasonable price for CAS NO 182230-43-9,182230-43-9,Voriconazole intermediate,Voriconazole advance intermediate,(2R,3S/2S,3R)-2-(2,4-Difluorophenyl), For more details, please get hold of us as soon as possible!
CAS NO 182230-43-9, With high quality, reasonable price, on-time delivery and customized & personalized services to help customers achieve their goals successfully, our company has got praise in both domestic and foreign markets. Buyers are welcome to contact us.

Related Products

Hot Products

  • 1-Hydroxyethylethoxypiperazine

    1-Hydroxyethylethoxypiperazine

    Product Name:1-Hydroxyethylethoxypiperazine
    Molecular Formula:C8H18N2O2
    Molecular Weight:174.24
    CAS Registry Number:13349-82-1
  • N,N,N-Trimethyl-1-ammonium adamantane

    N,N,N-Trimethyl-1-ammonium adamantane

    Product Name:N,N,N-Trimethyl-1-ammonium adamantane
    Molecular Formula:C13H25NO
    Molecular Weight:211.35
    CAS Registry Number:53075-09-5
  • L-Leucine

    L-Leucine

    Product Name:L-Leucine
    Molecular Formula:C6H13NO2
    Molecular Weight:131.17
    CAS Registry Number:61-90-5
  • Rimegepant sulfate

    Rimegepant sulfate

    Product Name:Rimegepant sulfate
    Molecular Formula:C28H30F2N6O7S
    Molecular Weight;632.64
    CAS Registry Number;1374024-48-2
  • 1-Methyl-1H-Pyrazole-4-Carboxylic Acid

    1-Methyl-1H-Pyrazole-4-Carboxylic Acid

    Product Name:1-Methyl-1H-Pyrazole-4-Carboxylic Acid
    Molecular Formula:C5H6N2O2
    Molecular Weight:126.11
    CAS Registry Number:5952-92-1
  • Folic Acid

    Folic Acid

    Product Name:Folic Acid
    Molecular Weight:441.40
    CAS Registry Number:59-30-3
  • Related Blog
  • Reviews

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept